IDH2 and acute myeloid leukemia: Reported 2–3-years overall survival in IDH-mutant AML ranges between 51 and 89% in the literature; discrepancies are thought to be related to differences in cohort age, but some authors also argue that different specific IDH mutations may carry varied prognostic implications (3, 44, 45, 47, 54, 56, 57).